Investigating the role of platelets in blood clot risks for cancer patients
Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer
This study is looking at how certain blood cells called platelets might affect the risk of blood clots in cancer patients, and it hopes to find a way to identify those who are more likely to develop these clots so that better prevention methods can be created.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-10531623 on NIH RePORTER |
What this research studies
This research focuses on understanding how platelets, a type of blood cell, contribute to the risk of blood clots in patients with cancer. It aims to identify a specific marker, platelet FcɣRIIa expression, that could help predict which cancer patients are at higher risk for developing venous thromboembolism (VTE) and experiencing cancer progression. By analyzing platelet samples from patients, the study seeks to improve current prevention strategies for blood clots, which are often inadequate. The research is conducted at the University of Vermont Cancer Center, leveraging an established clinical program dedicated to preventing VTE in outpatient settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are at high risk for developing venous thromboembolism.
Not a fit: Patients with non-cancer-related conditions or those not at risk for venous thromboembolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better identification of cancer patients at risk for blood clots, allowing for more effective prevention strategies.
How similar studies have performed: Previous research has shown that platelet markers can be indicative of thrombotic risks, suggesting potential success for this novel approach.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Holmes, Chris Elaine — University of Vermont & St Agric College
- Study coordinator: Holmes, Chris Elaine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.